This research proposes that K2's high adverse result occurrence is because of, at least partly, to distinctive JWH-018 metabolite activity on the cannabinoid one receptor (CB1R), and suggests that metabolites of most prescription drugs, but not the carboxy metabolite, retain in vitro and in vivo action at CB1Rs. Structure characterisation https://eam220121863.ja-blog.com/31175638/the-best-side-of-eam-2201